Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-08-08
2006-08-08
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S091100, C435S455000, C435S320100, C536S023100, C536S024310, C536S024500
Reexamination Certificate
active
07087580
ABSTRACT:
This invention relates to oligonucleotides complementary to the neuropilin genes which modulate tumor cell growth and angiogenesis in mammals. This invention is also related to methods of using such compounds in inhibiting the growth of tumor cells and angiogenesis in mammals. This invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.
REFERENCES:
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6391311 (2002-05-01), Ferrara
patent: 0128733 (1984-12-01), None
patent: WO94/08625 (1994-04-01), None
patent: WO9507994 (1995-03-01), None
patent: WO97/15662 (1997-01-01), None
patent: WO97/21808 (1997-06-01), None
patent: WO99/02556 (1999-01-01), None
patent: WO99/04263 (1999-01-01), None
patent: WO99/29729 (1999-06-01), None
Branch, TIBS 23 pp. 45-50, Feb. 1998.
Flanagan et al., Nature Biotech. 17: 48-52, Jan. 1999.
Crystal, Science 270: 404-410, Oct. 1995.
Ma et al. Biotechnology Annual Review, vol. 5, Jul. 19, 2000, pp. 155-196.
Jen et al. Stem Cells, vol. 18, 2000, pp. 307-319.
Green et al. J. Am. Coll. Surg., vol. 191, No. 1, Jul. 2000, pp. 93-105.
Agrawal et al. Molecular Medicine Today, vol. 6, Feb. 2000, pp. 72-81.
Bennett et al. , Chapter 2 from Methods in Molecular Medicine: Antisense Therapeutics (Ed. Agrawal), Humana. Press Inc. Totowa, N.J., 1996, pp. 13-46.
Sigmund, Thromb. Vasc. Biol., vol. 20, pp. 1425-1429, 2000.
Blackshear, Toxicologic Pathology, vol. 29, No. 1, pp. 105-116, 2001.
He. et al. Ce.., vol. 90: 739-751 (1997).
Soker et al. J. Biol. Chem. vol. 271(10): 5761-5767 (1996).
Milner et al. Nature Biotech. vol. 15:537-541 (1997).
Good and Nielsen; “Inhibition of translation and bacterial growth by polypeptide nucleic acid targeted to ribosomal RNA”, PNAS USA (1998) 95:2073-2076.
Sullivan, S.M., “Development of ribozymes for gene therapy”, J. Invest. Dermatol. 1(1994) 103(5 Suppl): 85S-89S.
Agrawal, S., “Antisense oligonucleotides: towards clinical trials” Trends Biotechnol., Oct. 1996, 14:376-387.
Crooke S.T., 1998 Antisense Research and Application: Basic Principles of Antisense Therapeutics Ch. 1 pp. 1-50.
Soker S. et al., 1998, Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(92): 735-745.
Curcio, L.D., Bouffard, D.Y., and Scanlon, K.J. Oligonucleotides as modulators of cancer gene expression, Pharmacol Ther. 74:317-32, 1997.
Narayanan, R. and Akhtar, S. Antisense therapy, Curr. Opin Oncol. 8:509-15, 1996.
Ho, P.T. and Parkinson, D.R., Antisense oligonucleotides as therapeutics for malignant diseases, Semin Oncol. 24:187-202, 1997.
Crooke, S.T. and Bennett, C.F. Progress in antisense oligonucleotide therapeutics, Annu Rev. Pharmacol. Toxicol. 36:107-29, 1996.
Mitsuhashi, M., “Strategy for designing specific antisense oligonucleotide sequences” J. Gastroenterol. 32:282-7, 1997.
Alama, A. et al., “Antisense oligonucleotides as therapeutic agents”, Pharmacol. Res. 36:171-8, 1997.
Brem, S. et al., “Prolonged tumor dormancy by prevention of neovascularization in the vitreous”, Cancer Res. 36:2807-12, 1976.
Holmgren, L. et al., “Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression”, Nat. Med. 1:149-53, 1995.
Parangi, S. et al., Antiangiogenic therapy of transgenic mice impairs de novo tumor growth, Proc. Acad. Natl. Sci. USA 93:2002-2007, 1996.
Uhlmann et al., Chem. Rev. 90:534-583, 1990.
Agrawal, Antisense Oligonucleotides as Antiviral agents, Trends Biotechnol. 10:152-158, 1992.
Smith et al., Oxygen-Induced Retinopathy in the Mouse, 1994. Invest. Ophthamol. Vis. Sci 35:101-111.
Pierce et al., Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization, 1995. Proc. Acad. Natl. Sci. USA 92:905-909.
Tischer, E. et al., “The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing”, J. Biol. Chem. 266:11947-54, 1991.
Poltorak, Z., et al., “VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix”, J. Biol. Chem. 272:7151-7158, 1997.
Terman, B.I., et al., “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem. Biophys. Res. Commun. 187:1579-86, 1992.
Millauer, B., et al. “High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis”, Cell. 72:835-846, 1993.
Shibuya, M., et al., “Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family”, Oncogene. 5:519-524, 1990.
De Vries, C., et al., “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”, Science. 255:989-991, 1992.
Kawakami, A., et al., “Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system”, J. Neurobiol. 29:1-17, 1996.
Takagi, S. et al., “Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system”, Dev. Biol. 170:207-222, 1995.
Soker, S. et al., “Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of FEGF165”, J. Biol. Chem. 272:31582-8, 1997.
He, Z. and Tessier-Lavigne, M. “Neuropilin is a receptor for the axonal chemorepellent Semaphorin III”, Cell. 90:739-51, 1997.
Eiglmeier et al., “Use of an ordered cosmid library to deduce the genomic organization ofMycobacterium leprae”, Molecular Microbiology, 1993, 7(2), pp. 197-206.
Walker et al., “Sequences of 20 Subunits of NADH: Ubiquinone Oxidoreductase from Bovine Heart Mitochondria”, J. Mol. Biol., 1992, vol. 226, pp. 1051-1072.
Lee Yoon S.
Wright Jim A.
Young Aiping H.
DLA Piper Rudnick Gray Cary US LLP
GeneSense Technologies Inc.
Zara Jane
LandOfFree
Neuropilin antisense oligonucleotide sequences and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuropilin antisense oligonucleotide sequences and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuropilin antisense oligonucleotide sequences and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3696255